IGM Biosciences Performance
| IGMSDelisted Stock | USD 1.27 0.03 2.31% |
The company retains a Market Volatility (i.e., Beta) of 0.24, which attests to not very significant fluctuations relative to the market. As returns on the market increase, IGM Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding IGM Biosciences is expected to be smaller as well. At this point, IGM Biosciences has a negative expected return of -0.11%. Please make sure to check out IGM Biosciences' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if IGM Biosciences performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days IGM Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
| Begin Period Cash Flow | 113.1 M | |
| Total Cashflows From Investing Activities | 64.2 M |
IGM |
IGM Biosciences Relative Risk vs. Return Landscape
If you would invest 132.00 in IGM Biosciences on July 2, 2025 and sell it today you would lose (5.00) from holding IGM Biosciences or give up 3.79% of portfolio value over 90 days. IGM Biosciences is currently does not generate positive expected returns and assumes 1.5874% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than IGM, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IGM Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IGM Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IGM Biosciences, and traders can use it to determine the average amount a IGM Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0706
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IGMS |
Estimated Market Risk
| 1.59 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IGM Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IGM Biosciences by adding IGM Biosciences to a well-diversified portfolio.
IGM Biosciences Fundamentals Growth
IGM Stock prices reflect investors' perceptions of the future prospects and financial health of IGM Biosciences, and IGM Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IGM Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | 0.0289 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | 0.91 % | ||||
| Current Valuation | (27.73 M) | ||||
| Shares Outstanding | 36.59 M | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 0.53 X | ||||
| Revenue | 2.68 M | ||||
| EBITDA | (199.47 M) | ||||
| Cash And Equivalents | 469.14 M | ||||
| Cash Per Share | 10.95 X | ||||
| Total Debt | 45.19 M | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | 1.68 X | ||||
| Cash Flow From Operations | (153 M) | ||||
| Earnings Per Share | (0.90) X | ||||
| Total Asset | 265.71 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Current Asset | 1.23 M | ||||
| Current Liabilities | 3.37 M | ||||
About IGM Biosciences Performance
Assessing IGM Biosciences' fundamental ratios provides investors with valuable insights into IGM Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the IGM Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Igm Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.Things to note about IGM Biosciences performance evaluation
Checking the ongoing alerts about IGM Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IGM Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IGM Biosciences is not yet fully synchronised with the market data | |
| IGM Biosciences generated a negative expected return over the last 90 days | |
| IGM Biosciences may become a speculative penny stock | |
| IGM Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.68 M. Net Loss for the year was (195.79 M) with loss before overhead, payroll, taxes, and interest of (5.49 M). | |
| IGM Biosciences currently holds about 469.14 M in cash with (153 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing IGM Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IGM Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining IGM Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IGM Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IGM Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IGM Biosciences' stock. These opinions can provide insight into IGM Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in IGM Stock
If you are still planning to invest in IGM Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IGM Biosciences' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |